Diagnosis and treatment integrated high molecular drug carrier material and application thereof

A carrier material and polymer technology, applied in wave energy or particle radiation treatment materials, drug combination, drug delivery, etc., can solve the problems of exacerbation of the disease, increase the pain of patients, delay the treatment time, etc., and achieve the effect of efficient treatment of tumors

Inactive Publication Date: 2019-02-15
WUHAN POLYTECHNIC UNIVERSITY
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, from diagnosis to drug treatment, part of the treatment time will inevitably be delayed, which will easily lead to untimely treatment and aggravate the patient's condition or increase the suffering of the patient.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Diagnosis and treatment integrated high molecular drug carrier material and application thereof
  • Diagnosis and treatment integrated high molecular drug carrier material and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] (1) Weigh 0.2g methotrexate (particle size 1μm) and 0.3g chitosan (particle size 1μm), each dispersed with 10mL of ethanol and mixed, then added to a 50mL flask, and kept at 60°C Lightly stirred for 2 hours to carry out covalent bond coupling reaction, and then galactosylation was carried out after the reaction was completed to obtain 0.4 g of liquid drug-loaded polymer suspension;

[0030] (2) Disperse 0.4 g of the prepared liquid drug-loaded polymer suspension in 100 mL of an aqueous solution of dodecylsulfonic acid sodium salt with a concentration of 1 mg / mL. After dispersing for 30 min, centrifuge at 20,000 g for 10 min to collect the precipitate , and washed with water under the same centrifugation conditions; then the water-washed product, 0.1 g of dopamine stabilized by sodium laurate and 0.025 g of 3-chloropropionic acid were added to 150 mL of distilled water, and kept stirring at 60 ° C for 12 h in the dark, and the reaction After completion, the product is pu...

Embodiment 2

[0032] (1) Weigh 0.4g of gemcitabine (particle size 5μm) and 0.5g polyethylene glycol (particle size 5μm), each dispersed with 10mL of folic acid solution and mix, then add to a 50mL flask, and keep away from light at 80°C Stir for 4 hours to carry out the covalent bond coupling reaction, and then carry out galactosylation after the reaction is completed to obtain 0.6 g of liquid drug-loaded polymer suspension;

[0033] (2) Disperse 0.6 g of the prepared liquid drug-loaded polymer suspension in 50 mL of an aqueous solution of polyallylamine hydrochloride with a concentration of 2 mg / mL. After dispersing for 30 min, centrifuge at 15000 g for 10 min to collect the precipitate , and washed with water under the same centrifugation conditions; then the washed product, 0.1 g of indocyanine green stabilized by sodium citrate and 0.025 g of Au nanoparticles were added to 150 mL of distilled water, and kept stirring and reacting at 60 ° C for 12 h in the dark, and the reaction After co...

Embodiment 3

[0035] (1) Weigh 0.5g of pyrrolidone (50μm in particle size) and 0.6g of polyaspartic acid (50μm in particle size), mix them with 10mL of paclitaxel solution, add them to a 50mL flask, and store them at 50°C. Stir for 5 hours to carry out the covalent bond coupling reaction, and then carry out galactosylation after the reaction is completed to obtain 0.8 g of liquid drug-loaded polymer suspension;

[0036] (2) Disperse 0.8 g of the prepared liquid drug-loaded polymer suspension in 200 mL of an aqueous solution of sodium dodecylsulfonate with a concentration of 0.5 mg / mL. After dispersing for 50 min, centrifuge at 25000 g for 20 min to collect the precipitate , and washed with water under the same centrifugation conditions; then the washed product, 0.2 g of sodium chloride-stabilized fluorocarbon nanoparticles and 0.03 g of Pt nanoparticles were added to 200 mL of distilled water, and kept stirring at 70 ° C for 18 h in the dark, and the reaction After completion, the product i...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
Login to view more

Abstract

The invention discloses a diagnosis and treatment integrated high molecular drug carrier material and application thereof. The diagnosis and treatment integrated high molecular drug carrier material comprises drug carrying polymer and photothermal particles, wherein the drug carrying polymer covers the photothermal particles and comprises active substance and a macromolecular drug carrier; the active substance is connected with the macromolecular drug carrier through a covalent bond; each photothermal particle comprises an inner nuclear layer and a shell layer coated on the surface of the inner nuclear layer; the inner nuclear layer is selected from an arbitrary one in graphene, carbon nanorod, indocyanine green, Prussian blue, CuS, ZnS, dopamine and perfluorocarbon nanoparticle; the shelllayer is selected from any one of 3-chloropropionic acid, allylamine hydrochloride polymer, sodium dodecyl sulfate, Au nanoparticle, Ag nanoparticle, Pt nanoparticle and hydrogenated palladium (PdH0.2) nanoparticle. The high molecular drug carrier material realizes the integration of diagnosis and treatment, and can be applied to both coherent contrast imaging and tumor therapy.

Description

technical field [0001] The invention relates to the technical field of pharmaceutical preparations, in particular to a diagnosis-treatment integrated polymer drug carrier material and its application. Background technique [0002] In traditional clinical practice, disease diagnosis and treatment are two relatively independent processes. For example, in the process of cancer diagnosis and treatment, diagnostic contrast agents and therapeutic drugs need to be used in the diagnosis and treatment stages, respectively. However, part of the treatment time will be delayed from diagnosis to drug treatment, which will easily lead to untimely treatment and aggravate the patient's condition or increase the pain of the patient. Contents of the invention [0003] The main purpose of the present invention is to propose a diagnosis-treatment integrated polymer drug carrier material and its application, aiming to provide a polymer drug carrier material capable of diagnosing and treating d...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K41/00A61K9/16A61K31/519A61K31/58A61K31/7072A61K47/58A61K47/59A61K47/61A61K47/64A61K49/22A61P35/00
CPCA61K9/167A61K31/519A61K31/58A61K31/7072A61K41/0052A61K47/58A61K47/59A61K47/61A61K47/645A61K49/225A61P35/00A61K2300/00
Inventor 陈继兵贺战文
Owner WUHAN POLYTECHNIC UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap